ImmunoCellular Therapeutics, Ltd. announced that in connection with the Company's intention to delist its Common Stock and Listed Common Stock Warrants, on October 10, 2018, Dr. Anthony Gringeri notified the Company that he resigned from the Board and as President and Chief Executive Officer of the Company, effective as of October 15, 2018. On the same date, David Fractor and Dr. Steven Swanson each notified the Company of his resignation as Chief Financial Officer and Senior Vice President, as applicable, in each case as of October 15, 2018. Thereafter, Dr. Gringeri, Mr. Fractor and Dr. Swanson are expected to serve as consultants to the Company.